United States Prenatal Diagnostic Market To Witness Huge Growth By 2030

By Author: Kavita Sharma
Total Articles: 78
Comment this article

The worldwide United States Prenatal Diagnostic market has recently been published by Absolute Markets Insights. The statistical report offers an appropriate analysis of recent trends and technological advancements in regions such as North America, Latin America, Asia-Pacific, Africa, and India. The data also uses useful tools, methodologies and standard operating procedures carried out by top-level industries to support its analysis. Moreover, the study also applies effective exploratory techniques such as primary and secondary research techniques. Some of the distinctive market key components of the United States Prenatal Diagnostic market have been studied in order to get an extensive idea about the requirements of the businesses. Financial and economic aspects of the businesses have also been presented by means of graphical presentation techniques such as charts, graphs, tables, and pictures. The entire demand and supply chain has been explained with the help of penetrative insights into the businesses.

Top Players of United States Prenatal Diagnostic Market are Studied: Laboratory Corporation of America Holdings, ...
... Eurofins NTD, LLC, Abbott Laboratories, Hologic Inc., Illumina, Inc., Natera, Inc., PerkinElmer, Inc., Sequenom, Inc., Ariosa Diagnostics, Inc., and Ravgen. Inc. amongst others.

Click to view the full report: https://www.absolutemarketsinsights.com/reports/United-States-Prenatal-Diagnostic-Market-2018-2026-17

United States Prenatal Diagnostics is used for testing the fetus before birth to determine certain hereditary disorders, for instance, Down's syndrome, hereditary sicknesses, chromosome abnormalities, neural tube defects, and other conditions. If high-risk is identified with the birth of a child, it can be assisted by conducting hereditary testing, common testing, and screening. The United States United States Prenatal Diagnostic market was valued at USD 527.5 Mn in 2020 and is expected to reach US$ 1,429.5+ Mn by 2030.

On the basis of test type, MaterniT21 PLUS Segment represented a major share in the U.S. United States Prenatal Diagnostic Market in 2016. The MaterniT21 PLUS test is indicated for use in pregnant women with increased risk for chromosomal aneuploidy. It analyzes circulating cell-free DNA extracted from a maternal blood sample. Rise in maternal age, and growing incidence of genetic abnormalities in newborns are the most significant drivers of these tests. Moreover, increased market penetration and competitive marketing methodologies by companies are further boosting the growth of these tests.

United States Prenatal Diagnostic Market:

By Type

Prenatest, Verify
Visibility
Harmony
InformaSeq
MaterniT21 PLUS
NIFTY
Panorama
Others)
By End-Use

Hospitals
Clinics
Others
By Region

North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Contact Us:

Company: Absolute Markets Insights

Email id: sales@absolutemarketsinsights.com

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

Website: https://www.absolutemarketsinsights.com/